Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Evolus, Inc. (EOLS : NSDQ)

• Company Description    Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. Number of Employees: 167

• Price / Volume Information    Yesterday's Closing Price: $13.18 Daily Weekly Monthly 20 Day Moving Average: 546,365 shares Shares Outstanding: 56.05 (millions) Market Capitalization: $738.73 (millions) Beta: 2.07 52 Week High: $14.30 52 Week Low: $5.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.84% 27.55% 12 Week 50.97% 63.17% Year To Date 102.46% 139.80%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 520 Newport Center Dr. Suite 1200 - Newport Beach,CA 92660 USA ph: 949-284-4555 fax: - ir@evolus.com http://www.evolus.com

• General Corporate Information    Officers David Moatazedi - President and Chief Executive Officer Vikram Malik - Chairman Lauren P. Silvernail - Chief Financial Officer and Executive Vice Preside Simone Blank - Director Robert Hayman - Director Peer Information Evolus, Inc. (BJCT) Evolus, Inc. (CADMQ) Evolus, Inc. (APNO) Evolus, Inc. (UPDC) Evolus, Inc. (IMTIQ) Evolus, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 30052C107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/03/22 Share - Related Items Shares Outstanding: 56.05 Most Recent Split Date: (:1) Beta: 2.07 Market Capitalization: $738.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.98 Price/Cash Flow: - Price / Sales: 6.09 EPS Growth vs. Year Ago Period: -293.75% vs. Previous Quarter: 6.06% Sales Growth vs. Year Ago Period: 177.00% vs. Previous Quarter: -2.16% ROE 03/31/22 - -80.20 12/31/21 - -60.65 09/30/21 - -145.33 ROA 03/31/22 - -30.31 12/31/21 - -21.53 09/30/21 - -27.23 Current Ratio 03/31/22 - 3.51 12/31/21 - 3.10 09/30/21 - 1.94 Quick Ratio 03/31/22 - 3.42 12/31/21 - 3.07 09/30/21 - 1.89 Operating Margin 03/31/22 - -58.28 12/31/21 - -46.96 09/30/21 - -65.32 Net Margin 03/31/22 - -58.28 12/31/21 - -46.96 09/30/21 - -162.78 Pre-Tax Margin 03/31/22 - -58.25 12/31/21 - -46.92 09/30/21 - -162.95 Book Value 03/31/22 - 1.20 12/31/21 - 1.47 09/30/21 - 1.75 Inventory Turnover 03/31/22 - 16.55 12/31/21 - 14.90 09/30/21 - 10.53 Debt-to-Equity 03/31/22 - 1.06 12/31/21 - 0.87 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 51.49 12/31/21 - 46.52 09/30/21 - 0.00

Powered by Zacks Investment Research ©